Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia

PURPOSE: While significant progress has been made in the treatment of T-cell acute lymphoblastic leukemia (T-ALL), many patients will require additional therapy for relapsed/refractory disease. Cyclin D3 (CCND3) and CDK6 are highly expressed in T-ALL and have been effectively targeted in mutant NOTC...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Cancer Res
Hoofdauteurs: Pikman, Yana, Alexe, Gabriela, Roti, Giovanni, Conway, Amy Saur, Furman, Andrew, Lee, Emily S., Place, Andrew E., Kim, Sunkyu, Saran, Chitra, Modiste, Rebecca, Weinstock, David M., Harris, Marian, Kung, Andrew L., Silverman, Lewis B., Stegmaier, Kimberly
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2016
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5432118/
https://ncbi.nlm.nih.gov/pubmed/28151717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2869
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items